Eli Lilly has launched a $6.75 billion debt offering divided into seven tranches, including $1 billion in 3-year fixed notes at a +28 basis points spread, $750 million in 3-year floating rate notes linked to SOFR at +53 basis points, $750 million in 5-year fixed notes at +40 basis points, $1 billion in 7-year fixed notes at +48 basis points, $1.25 billion in 10-year fixed notes at +57 basis points, $1 billion in 30-year fixed notes at +65 basis points, and $1 billion in 40-year fixed notes at +73 basis points. Eli Lilly shares rose by approximately 1% in premarket trading. The company is currently valued at its lowest level in 2.5 years, with insiders purchasing over $4.5 million in shares in the past 10 days. On the pharmaceutical front, Wall Street analysts view new obesity drugs as being priced similarly to Eli Lilly's Wegovy and Zepbound. Additionally, Eli Lilly has increased the price of its obesity treatment Mounjaro by 170% in the UK. Meanwhile, the weight-loss injection Ozempic faces $2 billion in lawsuits alleging serious side effects such as stomach paralysis, vision loss, and lasting health damage.